Macquarie Group’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-315
| Closed | -$9K | – | 2071 |
|
|
2024
Q1 | $9K | Sell |
315
-1,267
| -80% | -$35.5K | ﹤0.01% | 1595 |
|
|
2023
Q4 | $44K | Sell |
1,582
-1,730,710
| -100% | -$39.6M | ﹤0.01% | 1597 |
|
|
2023
Q3 | $38.8M | Sell |
1,732,292
-219,161
| -11% | -$8.15M | 0.05% | 477 |
|
|
2023
Q2 | $79.4M | Buy |
1,951,453
+308,303
| +19% | +$15.1M | 0.09% | 289 |
|
|
2023
Q1 | $79.6M | Buy |
1,643,150
+76,470
| +5% | +$3.5M | 0.09% | 287 |
|
|
2022
Q4 | $59.8M | Buy |
1,566,680
+4,462
| +0.3% | +$185K | 0.07% | 380 |
|
|
2022
Q3 | $78.5M | Sell |
1,562,218
-126,516
| -7% | -$6.2M | 0.1% | 285 |
|
|
2022
Q2 | $67.7M | Buy |
1,688,734
+135,806
| +9% | +$4.76M | 0.08% | 360 |
|
|
2022
Q1 | $57.9K | Buy |
1,552,928
+30,101
| +2% | +$1.16M | 0.04% | 477 |
|
|
2021
Q4 | $60.7M | Sell |
1,522,827
-48,614
| -3% | -$1.86M | 0.05% | 453 |
|
|
2021
Q3 | $58.5M | Buy |
1,571,441
+315,825
| +25% | +$13M | 0.05% | 474 |
|
|
2021
Q2 | $53.1M | Buy |
1,255,616
+106,835
| +9% | +$4.58M | 0.04% | 515 |
|
|
2021
Q1 | $54.4M | Buy |
1,148,781
+99,374
| +9% | +$5.9M | 0.08% | 315 |
|
|
2020
Q4 | $64M | Buy |
1,049,407
+97,229
| +10% | +$5.73M | 0.09% | 256 |
|
|
2020
Q3 | $44.5M | Buy |
952,178
+18,240
| +2% | +$898K | 0.08% | 296 |
|
|
2020
Q2 | $47.4M | Buy |
933,938
+132,241
| +16% | +$6.5M | 0.08% | 266 |
|
|
2020
Q1 | $35.8M | Buy |
801,697
+395,128
| +97% | +$19.9M | 0.07% | 283 |
|
|
2019
Q4 | $19.5M | Buy |
+406,569
| New | +$17.3M | 0.03% | 522 |
|
|
2018
Q3 | – | Sell |
-200
| Closed | -$7K | – | 2241 |
|
|
2018
Q2 | $7K | Buy |
+200
| New | +$6.24K | ﹤0.01% | 2138 |
|
|
2018
Q1 | – | Sell |
-600
| Closed | -$10K | – | 2327 |
|
|
2017
Q4 | $10K | Sell |
600
-4,500
| -88% | -$76.2K | ﹤0.01% | 2262 |
|
|
2017
Q3 | $102K | Buy |
+5,100
| New | +$99.8K | ﹤0.01% | 1912 |
|
|
2016
Q2 | – | Sell |
-40,643
| Closed | -$262K | – | 1628 |
|
|
2016
Q1 | $262K | Buy |
40,643
+933
| +2% | +$16.2K | ﹤0.01% | 1322 |
|
|
2015
Q4 | $1.29M | Sell |
39,710
-1,885
| -5% | -$55.5K | ﹤0.01% | 1032 |
|
|
2015
Q3 | $1.11M | Buy |
41,595
+1,927
| +5% | +$82.4K | ﹤0.01% | 1114 |
|
|
2015
Q2 | $1.91M | Buy |
39,668
+3,292
| +9% | +$192K | ﹤0.01% | 1037 |
|
|
2015
Q1 | $2.21M | Sell |
36,376
-6,550
| -15% | -$400K | ﹤0.01% | 988 |
|
|
2014
Q4 | $2.22M | Buy |
42,926
+9,307
| +28% | +$410K | ﹤0.01% | 988 |
|
|
2014
Q3 | $1.48M | Buy |
+33,619
| New | +$1.05M | ﹤0.01% | 1089 |
|
Other funds holding PTCT
RI
AC
CAC
CCM
Macquarie Group's PTCT Position: Q2 2024 in Review
Macquarie Group sold out of PTC Therapeutics (PTCT) in Q2 2024, closing a stake of 315 shares — an estimated $9K sold.
Macquarie Group first reported a position in PTCT in Q3 2014 and held it in 28 quarters. The position peaked at $79.6M in Q1 2023. 198 funds tracked by Wall St. Rank hold PTCT as of Q2 2024.
- Macquarie Group reported no remaining PTC Therapeutics position as of Q2 2024 after selling out during the quarter.
- Macquarie Group sold 315 PTC Therapeutics shares in Q2 2024, an estimated $9K.
- Macquarie Group first reported a position in PTC Therapeutics in Q3 2014 and held it in 28 quarters.
- Macquarie Group's PTC Therapeutics position peaked at $79.6M in Q1 2023.
- 198 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2024.
Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.